## FORM PTO-1449

## LIST OF PATENTS AND OTHER MS FOR APPLICANT'S INFORMATION DISCLOSE STATEMENT

ATTY. DOCKET NO. SERIAL NO. 892,280-484 APPLICANT 10/518802 Malabarba et a FILING DATE:

Not Yet Assigned

(Use several sheets if necessary)

				DTD91	Rec'd PCT/PT(	1 6 DE	2 0001
			U.S. P	ATENT DOCUMENTS		10 DE	2004
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
/K.C./	AA	5,139,778	08/1992	Selva et al.			
/K.C./	AB	5,200,429	04/1993	Sato et al.			
/K.C./	AC	5,380,763	01/1995	Sato et al.			
/K.C./	AD	5,599,791	02/1997	Tavecchia et al.			
/K.C.	AE	6,009,225	12/1999	Ciabatti et al.			
/K.C./	AF	6,143,739	11/2000	Pierfausto et al.			

Herewith

	FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN: YES	NO NO
/K.C./	AG	EP 0494078	07/1992	Europe				
/K.C./	AH	EP 0565567	01/1995	Europe				
/K.C./	Al	EP 0577356	01/1994	Europe				
/K.C./	AJ	WO 92/12172	07/1992	PCT				

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
/K.C./	AK	BERSON DS, Shalita AR. The treatment of acne: the role of combination therapies. J AM ACAD DERMATOL 1995; 32: 531-541.			
/K.C./	AL	CRAWFORD WW, Crawford IP, Stoughton RB, Cornell RC. Laboratory induction and clinical occurrence of combined clindanycin and erythromycin resistance in <i>Corynebacterium acnes</i> . J INVEST DERMATOL 1979; 72: 187-190.			
/K.C./	AM	EADY EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic-treated patients: association with therapeutic failure. BR J DERMATOL 1989; 121:51-7.			
/K.C./	AN	EBLING FJ., Cunliffe WJ. Disorders of sebaceous glands. In: Rook A., Wilkinson DS., Ebling FJ., Champion RH., Burton JL, eds. TEXTBOOK OF DERMATOLOGY. Vol III. Boston: Blackwell Scientific, 1992; 1699-744.			
/K.C./	AO	ESPERSEN F. Resistance to antibiotics used in dermatology practice. Br J DERMATOL 1998; 139 (53): 4-8.			

EXAMINER:	DATE CONSIDERED:					
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if						
not in conformance and not considered. Include a copy of this form with next communication to applicant.						

Information Disclosure Statement - Section 9 PTO-1449

FORM PTO-1449

LIST OF PATENTS AND OTHER MS FOR APPLICANT'S INFORMATION DISCLARE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO. SERIAL NO. 892,280-484
APPLICAND TO THE TOTAL TOTAL TO THE TOTAL TOTAL

Herewith

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
/K.C./	AP	HURWITZ S. The combined effect of vitamin A acid and benzoyl peroxide in the treatment of acne. Cuttis 1976; 17: 585-590.				
/K.C./	AQ	INGRAM E, Holland KT, Gowland C, et al. Studies of the extracellular proteolytic activity produced by <i>Propionibacterium acnes</i> . J APPL BACTERIOL 1983; 54:263-271.				
/K.C./	AR	KOO JYM, Smith LL. Psychologic aspects of acne. PEDIATR DERMATOL 1991; 8: 185-88.				
/K.C./	AS	KOO J. The psychosocial impact of acne: patients' perceptions. J AM ACAD DERMATOL 1995; 32: S26-S30.				
/K.C./	AT	LEYDEN JJ, McGinley KJ, Cavalieri S et al. <i>Propionibacterium acnes</i> resistance in acne patients. J AM ACAD DERMATOL 1983; 8: 41-5.				
· /K.C./	ВА	LEYDEN JJ. New understanding of the pathogenesis of acne. J AM ACAD DERMATOL 1995; 32: S15-S25.				
/K.C./	ВВ	MCEVOY GK, ed. AHFS drug Information. Bethesda, Md: American Society of Health System Pharmacists; 1996; pp. 374 and 2522.				
/K.C./	ВС	NORD CE. Treating acne with antibiotics leads to antibiotic resistance. Proceedings of the 101st Annual Meeting of ASM, Orlando May 2001.				
/K.C./	BD	PANZER, J.D. et al. "Acne Treatment: A Comparative Efficacy Trial of Clindamycin and Tetracycline", Cutis, EXCERPTA MEDICA 19(1): 109-111 (Jan. 1977)				
/K.C./	BE	PUHVEL SM, Sakamoto M. An in vitro evaluation of the inflammatory effect of purified comedonal components in human skin. J INVEST DERMATOL 1977; 69:401-406.				
/K.C./	BF	ROSS JI, Snelling AM, Eady EA, Cove JH, Cunliffe WJ et al. Phenotypic and genotypic characterization of antibiotic-resistant <i>Propionibacterium acnes</i> isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. BR J DERMATOL 2001; 144: 339-46.				
/K.C./	BG	SELVA, E. et al. "Antibiotic GE 2270 a: a novel inhibitor of bacgerial protein synthesis. I. Isolation and characterization." J. ANTIBIOTICS (Tokyo) 44(7): 693-701 (1991)				
/K.C.	/ ВН	SIEGLE RJ, Fekety R, Sarbone PD, et al. Effects of topical clindamycin on intestinal microflora in patients with acne. J AM ACAD DERMATOL 1986; 15: 180-5.				
/K.C./	ВІ	SYKES NL, Webster GF. Acne: a review of optimum treatment. DRUGS 1994; 48: 59-70.				
/K.C./	ВЈ	WALTERS CE, Ingham E, Eady EA, Cove JH, Kearney JN, Cunliffe WJ. In vitro modulation of keratinocyte-derived interleukin-1 alpha (IL-1 alpha) and peripheral blood mononuclear cell-derived IL-1 beta release in response to cutaneous commensal microorganisms. INFECT IMMUN 1995; 63:1223-28.				
/K.C./	ВК	WEBSTER GF. Inflammation in acne vulgaris. J AM ACAD DERMATOL 1995; 33:247-253.				
/K.C./	BL	WINSTON MH., Shalita AR. Acne vulgaris: pathogenesis and treatment. PEDIATR CLINIC NORTH AM 1991; 38:889-903.				
	ВМ					

١м١	

/Kendra Carter/

DATE CONSIDERED: 04/20/2009

01:20:2000

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.